Introduction
Therapeutic hypothermia following cardiac arrest can significantly reduce morbidity, mortality and neurological complications. 1, 2 There are several possible mechanisms by which therapeutic benefit is conferred. These include reducing cerebral metabolic rate for oxygen (CMRO 2 ) 3 and limiting reperfusion injury by reducing free radical production, excitatory amino acid release and calcium flux. 4, 5 The International Liaison Committee for Resuscitation (ILCOR) 6 recommends the use of therapeutic hypothermia as part of standard practice of care for comatose patients after ventricular fibrillation (VF) cardiac arrest. ILCOR suggests that the treatment may be effective for non-VF cardiac arrest but has not made a strong recommendation for this group. It also lays out basic standards of practice for the cooling and rewarming process. Induced hypothermia may have benefits if delayed for four to six hours, but the ILCOR guidelines state that hypothermia should be induced soon after return of spontaneous circulation (ROSC) with cooling for between 12 to 24 hours, followed by the gradual restoration of normothermia.
Increasing evidence for the efficacy of therapeutic hypothermia in routine clinical practice is emerging, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] but it still remains under-utilised. 18, 19 Although a recent telephone survey 20 suggested that the majority of intensive care units (ICUs) in the UK implement therapeutic hypothermia postarrest, there remains limited data on the actual effectiveness of cooling processes and outcome post-therapeutic hypothermia within the UK. 21, 22 Indeed, there remains scepticism among some clinicians on its use post-cardiac arrest. 23 We wanted to assess practice across a range of ICUs in north west England, to obtain information primarily on the cooling and rewarming processes, and secondarily to obtain outcome data on survival and neurological status at hospital discharge. We aimed to assess practice in clinical settings outside those of rigorously conducted, randomised controlled trials. The incidence of cooling-related complications was reviewed, as was the incidence of rebound hyperthermia on rewarming.
Methods
The Research and Development committee at Blackpool Victoria Hospital reviewed a submission for ethics approval. Therapeutic hypothermia is used to reduce mortality and morbidity following cardiac arrest. It is increasingly being used to cover a variety of indications including primary out-of-hospital ventricular fibrillation (VF) and non-VF cardiac arrests, in-hospital cardiac arrests and cardiac arrests of secondary cause. We have studied indications, techniques, efficiency, outcomes and complications of post-cardiac arrest cooling processes used in routine clinical practice in intensive care units in the north west of England. Survival at hospital discharge post-VF arrest was 53% in this multicentre cohort and all survivors at discharge had good or fair neurological recovery. This study confirms that our cooling and rewarming practices are effective and similar to those described in current literature, and meet standards set by the International Liaison Committee for Resuscitation (ILCOR). The project was accepted as an audit/service evaluation exercise and so formal ethical approval waiver was granted.
Cooling practices and outcome following therapeutic hypothermia for cardiac arrest
Nine ICUs from across the north west of England (Greater Manchester and Lancashire) submitted data on patients receiving intensive care post-cardiac arrest between 1st May 2010 and 31st July 2011. Anonymised data was collected prospectively using an online web-based proforma devised by one of the authors (BM). This database was set up under the auspices of the Association of North West ICUs as part of an audit and research collaborative project. Data entry was encouraged for all patients admitted to ICU post-cardiac arrest and who were subsequently cooled, regardless of location of arrest or presenting rhythm. Missing data were excluded from subsequent analysis.
Data collection was related specifically to the delay, duration and methods of cooling and rewarming and any associated complications. We analysed the time taken to reach target temperature for each cooling device used. Outcome data on survival and neurological status at discharge were collected.
Results
A total of 102 patients cooled post-cardiac arrest were entered into the database over a 15-month period from nine participating general hospitals and tertiary centres. One patient was entered twice, having had two cardiac arrests in quick succession. Hence outcome data were reviewed for 101 patients. Ninety-five patients had a primary cardiac cause for their arrest and six patients were cooled having had a cardiac arrest subsequent to non-cardiac pathology. Five patients had an in-hospital cardiac arrest.
The primary rhythm disturbance for the majority of patients who suffered cardiac arrest was VF (70/102) but with a significant proportion (31/102) having a non VF rhythm. The presenting rhythm was unknown in one patient. Eighty-two patients had bystander cardiopulmonary resuscitation (CPR) and 17 did not. Bystander CPR status for three patients is unknown.
The median age of patients included in this study was 61 years (IQR 47-72 years) (Figure 1 ) and the median time from arrest to return of spontaneous circulation (ROSC) was 20 minutes (IQR 10-34). The median Glasgow Coma Score on presentation was 3 (IQR 3-5) and the median ICU length of stay was 4.5 days.
The median time to initiation of cooling was 126 minutes (IQR 65 to 228). Figure 2 shows the distribution of time to initiation of cooling in this cohort. The target temperature was 32-34°C and was attained in all but one patient. The median time from ROSC to target temperature was 425 minutes (IQR 248-541). Distribution of time to target temperature is shown in Figure 3 . A range of cooling devices was used ( Table 1) , with external water circulating devices used most frequently. Analysis of median time to attaining target temperatures with varying devices used did not show a statistically significant difference (p value 0.09 between methods using the Median test).
The duration of the cooling process was defined as the time from initiation of cooling to start of rewarming. The median duration of cooling was 1,445 minutes (IQR 1,440-1,620). Target temperature was maintained for a median time of 1,275 minutes (IQR 1,040-1,395) (Figure 4 ).
The median time to rewarming to 36.5°C was 375 minutes (IQR 240-540) (Figure 5 ). The method of rewarming was recorded for 71 patients, with active rewarming being the favoured option. The average rewarming time for this group of patients was 398 minutes (median 360 minutes) as compared to 592 minutes (median 667 minutes) for patients who were passively rewarmed. Twenty-six patients experienced at least one deviation from target temperature. Five patients had deviations to a temperature below target and two had prolonged episodes of hypothermia.
Arrhythmias and cardiovascular instability were the most commonly reported cooling-related complications ( Table 2) . Rebound hyperthermia was a commonly reported phenomenon. Forty patients had temperatures above 37.5°C in the first 48 hours after the end of the rewarming process. The median temperature in this situation was 38.3°C.
Overall, 45% of cooled patients survived to discharge from ICU. For patients whose presenting arrhythmia was VF, 53% of patients survived to hospital discharge ( Table 3) . Neurological status at discharge was assessed using the Pittsburgh Cerebral Performance Category 24 (CPC). All 46 survivors at discharge had either good neurological recovery (Cerebral Performance Category 1=34) or moderate disability (Cerebral Performance Category 2=12). Fifteen patients discharged from ICU with either CPC 3 (severe disability) or CPC 4 (persistent vegetative state) subsequently died prior to hospital discharge.
Discussion
There is an increasing body of evidence confirming the benefits of mild therapeutic hypothermia in reducing mortality and neurological morbidity post-cardiac arrest. 1,2,7-17 Reputable bodies including the Resuscitation Council 25 and ILCOR 6 recommend the use of therapeutic hypothermia post-cardiac arrest. Our study has captured data on current cooling practices in a variety of ICUs in the north west of England and allows us to compare the implementation of therapeutic hypothermia to published series: two landmark randomised trials, 1,2 a European registry 8 and relevant literature from within the UK. 20, 21, 22 Eighty-nine of 95 patients entered into our study had cooling initiated within six hours from the return of spontaneous circulation, with a median delay of just over two hours (126 minutes, IQR 65-228). Similar delays were reported in the Hypothermia After Cardiac Arrest (HACA) study 2 (105 minutes) and the European Resuscitation Council Hypothermia after Cardiac Arrest registry 8 (131 minutes).
Time to attaining target temperature from ROSC has been used as an index of efficiency of the cooling process and could be used as a quality indicator. Whether a quicker time to cooling alters neurological outcome is unclear 26 and the subject of ongoing debate. Our median time from ROSC to target temperature was just over seven hours (425 minutes, IQR 248-541) with only one patient not reaching target temperature. In this respect, our practice is similar to the multicentre HACA European study, 2 which demonstrated a median time from ROSC to target temperature of eight hours (IQR 4-16). In comparison, Bernard et al 1 achieved target temperatures within two hours of ROSC, through the use of aggressive early cooling measures started in the pre-hospital setting and continued in hospital.
In comparison to published retrospective single-centre UK studies, we were able to cool 24% of our patients to target temperature within four hours (vs 51% in Hay et al 21 
Complication reported Incidence reported numbers
Arrhythmias (any episode 17 deemed as clinically significant) CVS instability (a clinically significant 12 deterioration in haemodynamics post commencement of cooling) Hypokalaemia (K + <3.5 mmol/L) 6
Hyperglycaemia (glucose >11 mmol/L) 5
Coagulopathy INR or APTTR >2 2 devices, but these differences were not statistically significant. This may perhaps be due to more efficient cooling processes in units using these methods and independent of the actual cooling method selected. The duration of cooling includes the time from initiation of cooling and the time spent at target temperature. Current practice in our region is again consistent with published series: the duration of cooling was 24.1 hours (24.0 hours in HACA 2 and 24.3 hours in European registry 8 ) and time at target temperature was 21.3 hours (17.5 hours in Gillies et al 22 ) . A recent UK-wide telephone survey showed that the majority of ICUs in the UK now implement therapeutic hypothermia post-VF arrest. 20 The median duration of cooling was 24 hours, with the commonest rewarming period between four and 12 hours. Our results are consistent with these findings.
The rewarming process post-cooling is also crucial and needs to be well controlled in order to prevent secondary reperfusion injury. The median time to rewarming to 36.5°C was 6.25 hours (375 minutes, IQR 240-540). Fourteen patients had a rewarming time of less than four hours, suggesting rewarming at quicker than ideal rates. Our median rewarming times are similar to those of Bernard et al 1 who aimed for a rewarming time over six hours using active warming with a warm air blanket. In comparison, patients in the HACA trial 2 were passively rewarmed, with a median rewarming period of eight hours (IQR 8-12) and participants entered into the European registry 8 had a median rewarming time of nine hours (6.8-12) . A comparison of our processes with that of other published studies 1,2 is outlined in Table 4 .
Rebound hyperthermia was a commonly reported phenomenon. Forty patients had temperatures above 37.5°C in the first 48 hours after the end of the rewarming process. This is perhaps an area of crucial importance given the frequency of reported events and the relation between pyrexia and secondary reperfusion injury to the brain. Complications of the cooling process were reported in 32 patients ( Table 2 ). The commonly reported events in order of occurrence were arrhythmias, cardiovascular instability, hypokalemia, hyperglycaemia and coagulopathy. The reporting of complications was the field least likely to be completed and it is quite feasible that our reported rates are under-estimates.
The survival to discharge rate was 53% when only VF arrests are considered and is in keeping with data from Bernard et al 1 and the HACA study group. 2 Death in one patient post-VF arrest was attributed to a dislodged tracheostomy, the patient having initially made some neurological recovery. Thirty of our patients treated with therapeutic hypothermia had rhythms other than VF. This reflects an increasing tendency among clinicians to treat these patients aggressively with cooling given the current uncertainty of benefit in this situation. There were 21 deaths (70%) and nine patients (30%) survived to hospital discharge in this group (Table 3) .
Overall, for all presenting rhythms, 45% of cooled patients survived to discharge. All 46 survivors at hospital discharge had either good or fair neurological recovery. Previous evidence also suggests that cooling does not increase the risk of longterm survival with severe neurological deficit or persistent vegetative state. 2 Our outcome data compares favourably with other registries. In a European registry 8 with 462 patients, 55% of patients (68% with VF as the presenting rhythm) cooled post-cardiac arrest had unfavourable outcomes including inhospital death and poor neurological recovery. In another recently published large French registry, 15 44% of patients post-VF arrest and only 15% of patients post non-VF arrest had good outcomes.
Patient entry onto our database was at the discretion of a responsible linkperson at each participating unit. The possibility of selection bias in entry onto our database cannot be excluded and is an issue with all voluntary registries. However this is unlikely, as the primary aim of our project was to assess cooling practices rather than outcome data.
Conclusion
The use of therapeutic hypothermia post-cardiac arrest is now well established in the UK. Data from our study confirm that the processes of cooling and rewarming are effective and in keeping with published randomised trials and ILCOR standards. Our demonstrated outcomes post-VF arrest are good, with a 53% survival to hospital discharge (Cerebral Performance Category 1 or 2) and are in keeping with published studies.
A significant proportion of patients entered were cooled post-non-VF/VT cardiac arrest, six patients had a non-cardiac cause for their cardiac arrest and five patients had an inhospital cardiac arrest. This may reflect an increasing tendency among clinicians to use therapeutic hypothermia in nonstandard clinical settings. The high incidence of rebound hyperthermia post cooling was unexpected and has led to increased awareness of this phenomenon. Our database allows the dissemination of information surrounding cooling practices and hence improves our standards of care for this group of patients. A UK-specific national registry, using a template similar to ours, would help inform best practice around the processes of cooling, allowing the continued development of standards for use in the prehospital, emergency department and critical care settings.
